Fruquintinib Patient Education and Management
Fruquintinib is a highly selective oral VEGFR inhibitor approved for patients with metastatic colorectal cancer who have failed all standard therapies including fluoropyrimidine, oxaliplatin, irinotecan, and prior anti-VEGF/anti-EGFR treatments (if RAS wild-type), and who have progressed on or are intolerant to TAS-102 and/or regorafenib. 1, 2
Dosing and Administration
Standard dosing: 5 mg orally once daily on days 1-21 of each 28-day cycle 2, 3
Key counseling point: Patients must take the medication consistently for 3 weeks, then have a 1-week break before starting the next cycle. This drug-free week is essential for toxicity management.
Critical Safety Monitoring and Management
Hypertension (Most Common Serious Adverse Event)
- Occurs in approximately 29% of patients (grade ≥3 in 11-14%) 4, 3
- Monitor blood pressure before each cycle and weekly during the first 2 cycles
- Initiate or adjust antihypertensive therapy promptly
- Hold fruquintinib if BP remains uncontrolled despite medical management 2
Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia)
- Affects approximately 19% of patients (grade ≥3 in 6%) 4
- Preventive counseling is essential:
- Apply thick moisturizing creams to hands and feet twice daily starting before treatment
- Avoid tight-fitting shoes and repetitive friction
- Use cooling measures (cold packs) for symptomatic relief
- For grade 2-3: dose reduction or temporary interruption required 2
Dose Modification Strategy
- First dose reduction: Reduce to 4 mg daily
- Second dose reduction: Reduce to 3 mg daily
- Discontinue if unable to tolerate 3 mg daily 2
Approximately 10% of patients require dose reduction, most commonly for hand-foot syndrome (5%), hypertension (3%), or proteinuria (1%) 4
Additional Adverse Events Requiring Monitoring
Proteinuria
- Monitor urine protein before each cycle 2
- Hold treatment for grade 3-4 proteinuria until recovery
Hepatotoxicity
- Check liver function tests before each cycle 2
- Dose modify or discontinue based on severity
Hemorrhagic Events
- Counsel patients to report any unusual bleeding immediately 2
- Avoid in patients with recent significant bleeding
Hypothyroidism
- Occurs in approximately 16% of patients 4
- Monitor thyroid function periodically
- Initiate thyroid replacement if indicated
Wound Healing Considerations
Hold fruquintinib at least 4 weeks before elective surgery and do not resume until adequate wound healing has occurred 2
Pregnancy and Contraception
Fruquintinib can cause fetal harm. Counsel patients of reproductive potential to:
- Use effective contraception during treatment and for 1 month after the final dose (females)
- Use effective contraception during treatment and for 1 week after the final dose (males with female partners) 2
Expected Efficacy Outcomes
Set realistic expectations: Median overall survival is approximately 7.4 months versus 4.8 months with placebo, representing a 2.6-month survival benefit 3. Disease control rate is approximately 62%, but objective response rate is only 5% 5. The goal is disease stabilization and symptom control, not tumor shrinkage.
Drug Interactions
Avoid strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) as they increase fruquintinib exposure 2
Quality of Life Considerations
Despite being heavily pretreated (median 4 prior lines of therapy), the safety profile is manageable with appropriate monitoring and dose modifications 3. Only 6% of patients discontinue due to treatment-related adverse events 4, indicating most toxicities are controllable.
When to Contact Healthcare Provider Immediately
- Severe headache, confusion, seizures, or vision changes (possible PRES)
- Severe abdominal pain (possible perforation)
- Chest pain or shortness of breath (possible arterial thrombosis)
- Uncontrolled blood pressure despite medication
- Severe bleeding
- Signs of infection with fever
Common Pitfall to Avoid
Do not continue fruquintinib at full dose through significant toxicity. Early dose reduction maintains treatment continuity and improves tolerability. The dose-escalation approach used with regorafenib is NOT standard for fruquintinib—start at full dose and reduce as needed 1.